Alternatives to mega-trials in cardiovascular disease

Cardiovascular Drugs and Therapy

Volumn 10, Issue 6, 1997, Pages 759-765

  Hampton, J R ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Cardiovascular trials; Equivalence trials; Meta analysis; Surrogate endpoints

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; CARDIOVASCULAR AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; KETANSERIN; RETEPLASE; STREPTOKINASE; TIMOLOL;

ACUTE HEART INFARCTION; BIOEQUIVALENCE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; DATA ANALYSIS; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HUMAN; META ANALYSIS; METHODOLOGY; MORTALITY; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

EID: 0030941971     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00053034     Document Type: Review

References (34)

1. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304: 801-807.
2. Wilcox RG, Von de Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR, for the ASSET Study Group. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Lancet 1988;2:525-530.
3. The International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990;336:71-75.
4. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: A randomised comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753-759.
5. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682.
6. Aspirin Myocardial Infarction Study Research Group. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 1980;243:661-669.
7. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
8. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
9. A randomised, blended trial of clopidogrel vs. aspirin in patients at risk of ischaemic events (CAPRIE), CAPRIE Steering Committee. Lancet 1996;348:1329-1339.
10. Teo KK, Yusuf S, Collins R, Held PH, Peto R. Effects of intravenous magnesium in suspected acute myocardial infarction: Overview of randomised trials. Br Med J 1991; 303:1499-1503.
11. Woods KL, Fletcher S, Roffe C, Haider Y. Intravenous magnesium sulphate in suspected acute myocardial infarction: Results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1992;339: 1553-58.
12. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-685.
13. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis 1985;27: 335-371.
14. β Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. 1. Mortality results. JAMA 1982;247:1707-1714.
15. Boissel J-P, Leizorovicz A, Picolet H, Peyrieux J-C for the APSI Investigators. Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. Am J Cardiol 1990;66:251-260.
16. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. Euro Heart J 1985;6:199-226.
17. ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986;2:57-66.
18. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435.
19. Cohn JN, Johnson G, Ziesche, et al., for The Vasodilator-Heart Failure Veterans Affairs Cooperative Study Group. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310.
20. Swedberg K, Held P, Kjekshus J, et al. on behalf of the CONSENSUS II Study Group. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. N Engl J Med 1992;327:678-684.
21. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-828.
22. Kober L, Torp-Pedersen C, Videbaaek CR, Egeblad H, on behalf or the TRACE Study Group. An echocardiographic method for selecting high risk patients shortly after acute myocardial infarction, for inclusion in multi-centre studies (as used in the TRACE Study). Eur Heart J 1994;15: 1616-1620.
23. Report of the Committee of Principal Investigators. WHO cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: Mortality follow-up. Lancet 1980;2:379-386.
24. Frick HM, Elo O, Haapa K, et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors and incidence of coronary heart disease. N Engl J Med 1987;317:1237-1245.
25. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. 1. Reduction in incidence of coronary heart disease. JAMA 1984;25: 351-364.
26. Hampton JR. Effects of antihypertensive therapy with diuretic drugs on morbidity and mortality. In: Progress in pharmacology and clinical pharmacology, Vol. 1013. Stuttgart: Gustav Fischer Verlag, 1995.
27. Prevention of Atherosclerotic Complications with Ketanserin Trial Group. Prevention of atherosclerotic complications: Controlled trial of ketanserin. Br Med J 1989;298: 424-430.
28. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321:406-412.
29. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-1475.
30. Cowley AJ, Skene AM, on behalf of the Enoximone Investigators. Treatment of severe heart failure: Quantity or quality of life? A trial of enoximone. Br Heart J 1994;72:226-230.
31. Hampton JR, Vanveldhuisen DN, Klebo FX, et al. Randomised study of the effect of ibopamine on survival in patients with moderate to severe heart failure. Lancet 1997, in press.
32. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329: 1616-1622.
33. International Joint Efficacy Comparison of Thrombolytics. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): Trial to investigate equivalence. Lancet 1995;346:329-336.
34. Smalling RW, Bode C, Kalbfleisch J, et al. on behalf of the RAPID Investigators. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995;91:2725-2732.